Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mepolizumab Long-term Access Programme for EGPA (post-MEA115921)
2014-003162-25Phase 3Completed
- Sponsor
- GSK
- Start
- Dec 2014
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of mepolizumab in eosinophilic granulomatosis with polyangiitis (EGPA), sponsored by GSK. Started Dec 2014; status: completed.
02
Drugs
mepolizumab
03
Conditions
eosinophilic granulomatosis with polyangiitis (EGPA)
Beyond the preview
Go deeper on 2014-003162-25.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-003162-25.